Evidence map›Paper›PMID 35198157›Full record

ArticleClinical kidney journal2022

Acute kidney injury requiring renal replacement therapy in people with COVID-19 disease in Ontario, Canada: a prospective analysis of risk factors and outcomes.

Jian Roushani, Doneal Thomas, Matthew J Oliver, Jane Ip, Yiwen Tang, Angie Yeung, Leena Taji, Rebecca Cooper, Peter O Magner, Amit X Garg and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. [Severe post-COVID-19 dialysis dependence and inpatient acute kidney injury].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jian RoushaniFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Doneal ThomasOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Matthew J OliverOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Jane IpOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Yiwen TangOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Angie YeungOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Leena TajiOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Rebecca CooperOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Peter O MagnerOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Amit X GargOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Peter G BlakeOntario Renal Network, Ontario Health, Toronto, ON, Canada.
Ontario Stroke Network · CAMcMaster University · CAUniversity of Ottawa · CAUniversity of Toronto · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeverely ill people with coronavirus disease 2019 (COVID-19) are at risk of acute kidney injury treated with renal replacement therapy (AKI-RRT). The understanding of the risk factors and outcomes for AKI-RRT is incomplete.

methodsWe prospectively collected data on the incidence, demographics, area of residence, time course, outcomes and associated risk factors for all COVID-19 AKI-RRT cases during the first two waves of the pandemic in Ontario, Canada.

resultsThere were 271 people with AKI-RRT, representing 0.1% of all diagnosed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases. These included 10% of SARS-CoV-2 admissions to intensive care units (ICU). Median age was 65 years, with 11% <50 years, 76% were male, 47% non-White and 48% had diabetes. Overall, 59% resided in the quintile of Ontario neighborhoods with the greatest ethnocultural composition and 51% in the two lowest income quintile neighborhoods. Mortality was 58% at 30 days after RRT initiation, and 64% at 90 days. By 90 days, 20% of survivors remained RRT-dependent and 31% were still hospitalized. On multivariable analysis, people aged >70 years had higher mortality (odds ratio 2.4, 95% confidence interval 1.3, 4.6). Cases from the second versus the first COVID-19 wave were older, had more baseline comorbidity and were more likely to initiate RRT  >2 weeks after SARS-CoV-2 diagnosis (34% versus 14%; P < 0.001).

conclusionsAKI-RRT is common in COVID-19 ICU admissions. Residency in areas with high ethnocultural composition and lower socioeconomic status are strong risk factors. Late-onset AKI-RRT was more common in the second wave. Mortality is high and 90-day survivors have persisting high morbidity.

Indexed as

acute dialysisacute kidney injuryCOVID-19renal replacement therapy

Identifiers

PMID35198157
PMCPMC8690186
OpenAlexW3217705678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.